Research programme: anti-VEC monoclonal antibodies - Eli Lilly and Company
Alternative Names: Anti-vascular endothelial cadherin monoclonal antibodies-Eli Lilly and Company; E4G10; VE-cadherin MAbLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 24 Nov 2008 ImClone Systems has been acquired by Eli Lilly and Company
- 15 Apr 1999 New profile